Loading clinical trials…
Loading clinical trials…
Loading clinical trial map…
Clinical trials
Registered study sites per country, as entered by registrants on ClinicalTrials.gov. A study with 40 sites in one country weighs 40 there; the trials column counts each study once per country.
Scope: all oncology trials · Phase 4 · all site statuses. Trials = distinct studies with ≥ 1 site in a named country; the per-country trial column sums to more because multinational studies count once per country.
City-level dots appear when a cancer is selected (the whole-registry city aggregate is too heavy to run per request).
Not drawn at this scale (4): Hong Kong 30, Singapore 30, Guadeloupe 1, Reunion 1. They are in the table.
| # | Country | ISO3 | Sites | Trials | Share of sites | Class | Trials list |
|---|---|---|---|---|---|---|---|
| 1 | United States | USA | 3,751 | 591 | 24.2% | 152–3,751 | View trials → |
| 2 | China | CHN | 1,549 | 520 | 10% | 152–3,751 | View trials → |
| 3 | Spain | ESP | 1,392 | 151 | 9% | 152–3,751 | View trials → |
| 4 | Germany | DEU | 1,063 | 130 | 6.9% | 152–3,751 | View trials → |
| 5 | Italy | ITA | 882 | 138 | 5.7% | 152–3,751 | View trials → |
| 6 | France | FRA | 815 | 144 | 5.3% | 152–3,751 | View trials → |
| 7 | India | IND | 539 | 61 | 3.5% | 152–3,751 | View trials → |
| 8 | United Kingdom | GBR | 414 | 96 | 2.7% | 152–3,751 | View trials → |
| 9 | Netherlands | NLD | 375 | 100 | 2.4% | 152–3,751 | View trials → |
| 10 | Canada | CAN | 319 | 124 | 2.1% | 152–3,751 | View trials → |
| 11 | South Korea | KOR | 288 | 125 | 1.9% | 152–3,751 | View trials → |
| 12 | Brazil | BRA | 282 | 49 | 1.8% | 152–3,751 | View trials → |
| 13 | Russia | RUS | 272 | 48 | 1.8% | 152–3,751 | View trials → |
| 14 | Belgium | BEL | 270 | 56 | 1.7% | 152–3,751 | View trials → |
| 15 | Japan | JPN | 256 | 39 | 1.7% | 152–3,751 | View trials → |
| 16 | Australia | AUS | 245 | 43 | 1.6% | 152–3,751 | View trials → |
| 17 | Poland | POL | 226 | 69 | 1.5% | 152–3,751 | View trials → |
| 18 | Taiwan | TWN | 193 | 83 | 1.2% | 152–3,751 | View trials → |
| 19 | Turkey (Türkiye) | TUR | 152 | 50 | 1% | 152–3,751 | View trials → |
| 20 | Sweden | SWE | 148 | 61 | 1% | 44–148 | View trials → |
| 21 | Denmark | DNK | 133 | 73 | 0.9% | 44–148 | View trials → |
| 22 | Mexico | MEX | 126 | 27 | 0.8% | 44–148 | View trials → |
| 23 | Hungary | HUN | 124 | 32 | 0.8% | 44–148 | View trials → |
| 24 | Czechia | CZE | 114 | 39 | 0.7% | 44–148 | View trials → |
| 25 | Austria | AUT | 112 | 37 | 0.7% | 44–148 | View trials → |
| 26 | Egypt | EGY | 101 | 80 | 0.7% | 44–148 | View trials → |
| 27 | Finland | FIN | 92 | 35 | 0.6% | 44–148 | View trials → |
| 28 | Israel | ISR | 90 | 32 | 0.6% | 44–148 | View trials → |
| 29 | Norway | NOR | 89 | 30 | 0.6% | 44–148 | View trials → |
| 30 | Argentina | ARG | 80 | 21 | 0.5% | 44–148 | View trials → |
| 31 | Switzerland | CHE | 74 | 37 | 0.5% | 44–148 | View trials → |
| 32 | Romania | ROU | 71 | 22 | 0.5% | 44–148 | View trials → |
| 33 | South Africa | ZAF | 71 | 12 | 0.5% | 44–148 | View trials → |
| 34 | Bulgaria | BGR | 69 | 17 | 0.4% | 44–148 | View trials → |
| 35 | Greece | GRC | 66 | 29 | 0.4% | 44–148 | View trials → |
| 36 | Thailand | THA | 53 | 28 | 0.3% | 44–148 | View trials → |
| 37 | Portugal | PRT | 50 | 18 | 0.3% | 44–148 | View trials → |
| 38 | Slovakia | SVK | 44 | 12 | 0.3% | 44–148 | View trials → |
| 39 | Hong Kong | HKG | 30 | 19 | 0.2% | 12–30 | View trials → |
| 40 | Singapore | SGP | 30 | 18 | 0.2% | 12–30 | View trials → |
| 41 | Malaysia | MYS | 29 | 13 | 0.2% | 12–30 | View trials → |
| 42 | Peru | PER | 23 | 8 | 0.1% | 12–30 | View trials → |
| 43 | Colombia | COL | 22 | 9 | 0.1% | 12–30 | View trials → |
| 44 | New Zealand | NZL | 21 | 9 | 0.1% | 12–30 | View trials → |
| 45 | Puerto Rico | PRI | 20 | 8 | 0.1% | 12–30 | View trials → |
| 46 | Croatia | HRV | 19 | 11 | 0.1% | 12–30 | View trials → |
| 47 | Chile | CHL | 18 | 10 | 0.1% | 12–30 | View trials → |
| 48 | Lithuania | LTU | 18 | 8 | 0.1% | 12–30 | View trials → |
| 49 | Lebanon | LBN | 17 | 13 | 0.1% | 12–30 | View trials → |
| 50 | Serbia | SRB | 17 | 8 | 0.1% | 12–30 | View trials → |
| 51 | Ukraine | UKR | 15 | 3 | 0.1% | 12–30 | View trials → |
| 52 | Ireland | IRL | 14 | 7 | 0.1% | 12–30 | View trials → |
| 53 | Iran | IRN | 12 | 6 | 0.1% | 12–30 | View trials → |
| 54 | Philippines | PHL | 12 | 5 | 0.1% | 12–30 | View trials → |
| 55 | Latvia | LVA | 11 | 7 | 0.1% | 3–11 | View trials → |
| 56 | Pakistan | PAK | 11 | 10 | 0.1% | 3–11 | View trials → |
| 57 | Saudi Arabia | SAU | 11 | 10 | 0.1% | 3–11 | View trials → |
| 58 | Bosnia and Herzegovina | BIH | 10 | 4 | 0.1% | 3–11 | View trials → |
| 59 | Slovenia | SVN | 10 | 8 | 0.1% | 3–11 | View trials → |
| 60 | Vietnam | VNM | 10 | 8 | 0.1% | 3–11 | View trials → |
| 61 | Estonia | EST | 9 | 6 | 0.1% | 3–11 | View trials → |
| 62 | Indonesia | IDN | 9 | 9 | 0.1% | 3–11 | View trials → |
| 63 | Venezuela | VEN | 9 | 5 | 0.1% | 3–11 | View trials → |
| 64 | Jordan | JOR | 7 | 6 | 0% | 3–11 | View trials → |
| 65 | Tunisia | TUN | 7 | 5 | 0% | 3–11 | View trials → |
| 66 | Ecuador | ECU | 6 | 3 | 0% | 3–11 | View trials → |
| 67 | Costa Rica | CRI | 5 | 5 | 0% | 3–11 | View trials → |
| 68 | Eswatini | SWZ | 5 | 1 | 0% | 3–11 | View trials → |
| 69 | Kenya | KEN | 5 | 3 | 0% | 3–11 | View trials → |
| 70 | Nigeria | NGA | 5 | 3 | 0% | 3–11 | View trials → |
| 71 | Bangladesh | BGD | 4 | 4 | 0% | 3–11 | View trials → |
| 72 | Iceland | ISL | 4 | 4 | 0% | 3–11 | View trials → |
| 73 | Belarus | BLR | 3 | 3 | 0% | 3–11 | View trials → |
| 74 | Morocco | MAR | 3 | 1 | 0% | 3–11 | View trials → |
| 75 | Albania | ALB | 2 | 2 | 0% | 1–2 | View trials → |
| 76 | Algeria | DZA | 2 | 1 | 0% | 1–2 | View trials → |
| 77 | Guatemala | GTM | 2 | 2 | 0% | 1–2 | View trials → |
| 78 | Iraq | IRQ | 2 | 2 | 0% | 1–2 | View trials → |
| 79 | Kazakhstan | KAZ | 2 | 1 | 0% | 1–2 | View trials → |
| 80 | Panama | PAN | 2 | 2 | 0% | 1–2 | View trials → |
| 81 | Syria | SYR | 2 | 2 | 0% | 1–2 | View trials → |
| 82 | Tanzania | TZA | 2 | 2 | 0% | 1–2 | View trials → |
| 83 | Cyprus | CYP | 1 | 1 | 0% | 1–2 | View trials → |
| 84 | Guadeloupe | GLP | 1 | 1 | 0% | 1–2 | View trials → |
| 85 | Kuwait | KWT | 1 | 1 | 0% | 1–2 | View trials → |
| 86 | Malawi | MWI | 1 | 1 | 0% | 1–2 | View trials → |
| 87 | Oman | OMN | 1 | 1 | 0% | 1–2 | View trials → |
| 88 | Qatar | QAT | 1 | 1 | 0% | 1–2 | View trials → |
| 89 | Reunion | REU | 1 | 1 | 0% | 1–2 | View trials → |
| 90 | Sudan | SDN | 1 | 1 | 0% | 1–2 | View trials → |
| 91 | Uganda | UGA | 1 | 1 | 0% | 1–2 | View trials → |
| 92 | United Arab Emirates | ARE | 1 | 1 | 0% | 1–2 | View trials → |
| 93 | Uruguay | URY | 1 | 1 | 0% | 1–2 | View trials → |
| 94 | Zambia | ZMB | 1 | 1 | 0% | 1–2 | View trials → |
Data updated 17 hours agoSource updated unknown94 countries · formula ci-trial-sites-v1 · source: clinicaltrials
Site counts come from the locations entered by registrants (a study with 40 US sites weighs 40 in the United States). “Recruiting” is the location status when the registrant provided one; otherwise the study’s overall status is used. Interventional and observational studies are both included; the country name is the registrant’s. Historical names without an ISO 3166-1 code (Serbia and Montenegro, Federal Republic of Yugoslavia, Netherlands Antilles) are listed without ISO3 and not painted.
Classes are quantiles of the displayed metric over countries with at least one site, recomputed for every filter, so colours are comparable within one view, not across views. Numbers, not colours, carry the meaning: hover or focus a country, or read the table. The “View trials” link filters the trials list by country. Full method.
Permalink: /trials/map?phase=PHASE4